Rosa A. van Amerongen

Rosa A. van Amerongen

Auto-generated profile, based on publicly available information

Rosa A. van Amerongen

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RARosa A van Amerongen
Rosa A van Amerongen
RHRenate S Hagedoorn
Renate S Hagedoorn
DRDennis F G Remst
Dennis F G Remst
DADanique C Assendelft
Danique C Assendelft
DSDirk M van der Steen
Dirk M van der Steen
MHMirjam H M Heemskerk
Mirjam H M Heemskerk
Background Transcription factor Wilms’ tumor gene 1 (WT1) is an ideal tumor target based on its expression in a wide range of tumors, low-level expression in normal tissues and promoting role in cancer progression. In clinical trials, WT1 is targeted using peptide-based or dendritic cell-based vaccines and T-cell receptor (TCR)-based therapies. Antitumor reactivities were reported, but T-cell reactivity is hampered by self-tolerance to WT1 and limited number of WT1 peptides, which were thus far selected based on HLA peptide binding algorithms. Methods In this study, we have overcome both limitations by searching in the allogeneic T-cell repertoire of healthy donors for high-avidity WT1-specific T cells, specific for WT1 peptides derived from the HLA class I associated ligandome of primary leukemia and ovarian carcinoma samples. Results Using broad panels of malignant cells and healthy cell subsets, T-cell clones were selected that demonstrated potent and specific anti-WT1 T-cell reactivity against five of the eight newly identified WT1 peptides. Notably, T-cell clones for WT1 peptides previously used in clinical trials lacked reactivity against tumor cells, suggesting limited processing and presentation of these peptides. The TCR sequences of four T-cell clones were analyzed and TCR gene transfer into CD8+ T cells installed antitumor reactivity against WT1-expressing solid tumor cell lines, primary acute myeloid leukemia (AML) blasts, and ovarian carcinoma patient samples. Conclusions Our approach resulted in a set of naturally expressed WT1 peptides and four TCRs that are promising candidates for TCR gene transfer strategies in patients with WT1-expressing tumors, including AML and ovarian carcinoma.

26 June 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
The efficacy of most immunotherapies for prostate cancer is limited by poor tumor immunogenicity as evidenced by minimal T-cell infiltration. Treatment with T cells engineered to express T-cell receptors (TCR) targeting prostate-specific antigens offers a potential solution by bypassing endogenous T-cell repertoire limitations. Through differential gene expression analysis, we have identified kallikrein-related peptidases 2, 3, and 4 (KLK2, KLK3, and KLK4) and homeobox B13 (HOXB13) as strictly prostate lineage–specific genes with high expression in prostate cancer and no expression in healthy tissues of risk. Naturally processed peptides derived from these antigens were identified, enabling T-cell enrichment using peptide–MHC multimers. High-avidity T cells targeting these antigens were isolated from allogeneic HLA-mismatched donors. After screening for on-target tumor specificity and absence of off-target reactivity, TCRs recognizing KLK4 in HLA-A*02:01 and KLK3 in HLA-B*35:01 were sequenced and further tested. TCRs were expressed in T cells through TCR gene transfer and TCRs with best performance were selected. Using combinatorial peptide library scanning, the cross-reactive potential of the KLK4-A2 and KLK3-B35 TCRs was analyzed. The KLK3-B35 TCR exhibited cross-reactivity against two additional peptides derived from LOXHD1 and CDH23, with broad tissue expression, and was therefore excluded. The KLK4-A2 TCR was highly specific for the KLK4 peptide. Further testing confirmed effective cytotoxic killing potential of KLK4-A2 TCR in vitro and in vivo, underscoring its therapeutic potential. These findings highlight the promise of the KLK4-A2 TCR for prostate cancer immunotherapy and demonstrate that prostate-specific antigens can be effectively targeted using TCR gene transfer strategies.

1 August 2025
Verified
Other
Open access
PDF file
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
IFN-ƴ production (ng/mL) of T cell clones 23.1A6 (KLK4-A2) and 36.2.2E3 (KLK3-B35) after overnight coculture with various HLA and KLK transduced Raji cells (E:T=1:6). Raji cells endogenously express HLA-A*03:01, HLA-B*15:10 and HLA-C*04:01. HLA target and KLK target indicates the specificity of the T-cell clone. Bars represent mean and SD of technical duplicates. (E:T: effector:target ratio)


1 August 2025
Verified
Other
Open access
PDF file
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
Boxplots depicting (A) SPDEF, (B) PRAC1, and (C) NKX3-1 expression in prostate cancer (TCGA data, n=30), healthy prostate (TCGA data, n=30) and across 51 (GTEx data, n=5-20) healthy tissue types, respectively. Red, green, grey and white boxplots represent prostate cancer, healthy prostate, testis and all remaining healthy tissues, respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. The upper black, lower black and red dashed lines represent the median expression value, the 10 fold lower expression value and the 80 fold lower expression value, respectively. X-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)